CPhI Worldwide 2020
วันที่ 13 - 15 ตุลาคม 2563
ณ Fiera Milano, Italy
Fierce competition in the low cost, high volume API sector is forcing suppliers to invest in capacity and accelerate throughput. Despite repeated quality concerns, China is likely to retain its leadership of the volume API sector, in part, thanks to new regulations.
India, a major producer and exporter of (generic) drugs, is concerned about over-reliance on China. In response, the Indian Government has introduced measures to boost local production. Similar efforts are being considered in the US. This creates a significant opportunity for volume API firms that are willing to invest in manufacturing capacity in India and the US
At the same time the drug industry is increasingly interested in higher potency, combination and niche drugs. For API companies that are willing to invest in the relevant expertise and capacity (particularly containment) there is a real opportunity.
API suppliers that can prove the security of their supply chains from raw materials through to ingredient, are likely to see considerable demand from pharmaceutical firms.
Growth of the generic sector in major markets, particularly the US and Europe, will cement their position as key targets for API manufacturers.
Emerging markets are growing in importance for API firms. The growth of life-style diseases in particular is creating a significant opportunity.
ลงทะเบียน
ไทย
